Rapidly decreasing level of prostate-specific antigen during initial androgen deprivation therapy is a risk factor for early progression to castration-resistant prostate cancer: A retrospective study

To build a practical model for predicting the progression to castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT). In all, 185 patients with prostate cancer who had received ADT as the primary therapy at our institution, from 2003 to 2014, were retrospectively enrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Guangjie, Song, Gang, Huang, Cong, He, Shiming, Zhou, Liqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392679/
https://www.ncbi.nlm.nih.gov/pubmed/28885333
http://dx.doi.org/10.1097/MD.0000000000007823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392679/
https://www.ncbi.nlm.nih.gov/pubmed/28885333
http://dx.doi.org/10.1097/MD.0000000000007823

Ejemplares similares